The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Overview of attention for article published in Arthritis Research & Therapy, July 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 34 publications that cite this research output.

34

The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Article in Annals of the Rheumatic Diseases (April 2024)

The Contribution of Serum Sialic Acid Binding Immunoglobulin-Like Lectin 1(sSIGLEC-1) as an IFN I Signature Biomarker in the Progression of Atherosclerosis in Egyptian Systemic Lupus Erythematosus (SLE) Patients

Article in Indian Journal of Clinical Biochemistry (September 2023)

CD169 expression on monocytes as a marker for assessing type I interferon status in pediatric inflammatory diseases

Article in Clinical Immunology (April 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.